Harmony Biosciences Names New CEO; CMO Sold $3M Weeks Ago
Harmony Biosciences announced COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, triggering a 5%-plus market sell-off. The timing is notable: CMO Kumar Budur sold $3.11 mil
Harmony Names New CEO; CMO Sold $3M Weeks Earlier
NEW YORK, October 13 —
When Harmony Biosciences Holdings, Inc. (HRMY) announced a CEO transition Monday, the market's 5%-plus sell-off landed on a company whose own Chief Medical Officer had quietly liquidated $3.11 million in stock at $41.98, $43.10 per share three weeks prior, prices now sitting above the current $37.76 close.
- Full-year 2026 Wakix revenue guidance reiterated at $1 billion to $1.04 billion per the 8-K filing.
- CMO Kumar Budur sold ~72,406 shares across seven transactions, September 4-18, 2026.
- HRMY trades at 5.4x forward earnings, versus analyst consensus target of $47.64.
The Transition the Market Didn't Price In
Harmony makes WAKIX (pitolisant), the only FDA-approved histamine H3 receptor antagonist for excessive daytime sleepiness in adult narcolepsy patients, a single-product commercial franchise generating $0.96 billion in trailing revenue at 30.3% growth. COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, per the 8-K; Dayno moves to an advisory role through year-end 2027. The guidance reaffirmation in the same release was clearly intended as a continuity signal. The market read the leadership change as risk, not reassurance, and the CMO's filing history helps explain why.
What the Form 4s Reveal
Budur exercised options at $30.27, $30.69 per share across the same September 4-18 window, then immediately sold the resulting shares at market prices of $41.98, $43.10, clearing the full position. His largest single transaction, 35,852 shares at $43.05 on September 18, generated $1.54 million alone. No insider purchases appear in the 90-day record; the entire $3.11 million in reported insider activity was open-market sales by the CMO. Routine option-and-sell execution is common. The timing, three and a half weeks before a board-level succession announcement, is the variable that warrants scrutiny, not the mechanics.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| HRMY | $2.2B | 5.4x | +42.4% |
| KYMR | $9.3B | n/a | +92.4% |
| INBX | $1.3B | n/a | +160.1% |
| KROS | $231M | n/a | -23.1% |
| PCVX | $11.2B | n/a | +64.9% |
| RLAY | $3.9B | n/a | +198.2% |
What to Watch From Here
The thesis that guidance integrity justifies the stock depends on Harmony's earnings trajectory holding. The most recent quarter delivered a 30.5% EPS beat, $1.50 actual versus $1.15 estimated, after two consecutive misses of -46.9% and -16.0%. At 5.4x forward earnings, the valuation already discounts execution risk heavily. HC Wainwright maintained its Buy with a $55 target as of October 13. The number that resolves the leadership-discount debate is Q4 Wakix revenue: a print at the top of the $1 billion, $1.04 billion range would argue the sell-off was noise. A miss would confirm the market's instinct. Run the free Harmony Biosciences Holdings, Inc. deep-dive →
Current fundamentals, valuation and filing history for Harmony Biosciences Holdings, Inc. (HRMY) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Who is Harmony Biosciences' new CEO?
Peter Anastasiou, the company's Chief Operating Officer, will take over as CEO on January 1, 2027, replacing Jeffrey Dayno. Dayno will move to an advisory role through year-end 2027.
Why did Harmony Biosciences stock fall?
The market treated the CEO transition as a risk signal rather than continuity. CMO Kumar Budur's sale of $3.11 million in stock three weeks prior to the announcement intensified investor concerns about management confidence in the transition.
What is Harmony Biosciences' main product?
Harmony's sole product is Wakix (pitolisant), the only FDA-approved histamine H3 receptor antagonist for excessive daytime sleepiness in narcolepsy patients. It generated $0.96 billion in trailing revenue with 30.3% annual growth.
When did the Harmony CMO sell stock?
CMO Kumar Budur sold 72,406 shares across seven transactions between September 4-18, 2026, at prices of $41.98, $43.10 per share, three weeks before the October 13 CEO transition announcement.
What is the analyst price target for Harmony?
The analyst consensus price target is $47.64. At the current price of $37.76, the stock trades at 5.4x forward earnings, with HC Wainwright maintaining a Buy rating and $55 price target as of October 13.
Harmony Biosciences announced Monday that COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, sending shares down more than 5% even as the company simultaneously reaffirmed its $1 billion Wakix revenue target. The announcement follows the company's Chief Medical Officer selling approximately $3.11 million in stock at prices now above the post-announcement share price.